SCHEMBL24478753

SCHEMBL24478753

O=C(OCc1ccccc1)c1cc(I)c2ncnc(O)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.48
▸ TDP1 Q9NUW8 4/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ SLC6A2 P23975 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ RAB9A P51151 5/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HPGD P15428 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ JMJD6 Q6NYC1 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22732548 0.85 LMNA (0.47) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL22732315 0.84 LMNA (0.46) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL22732543 0.83 MAPT (0.47) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL22732370 0.79 LMNA (0.55) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL24674535 0.78 TDP1 (0.50) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL6725779 0.78 KMT2A (0.64) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL19779307 0.76 TDP1 (0.66) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL22732437 0.74 HPGD (0.47) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL23196246 0.73 KMT2A (0.48) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL6282770 0.72 KMT2A (0.81) LMNATDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 — — US disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 — — US disclosed
WO-2022112490-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 LMNA 3348/4885TDP1 2286/4885KMT2A 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback